Diabetes Flashcards
microvascular complications
retinopathy - damage to retina can lead to blindness
neuropathy - damage to nerves and loss of sensation
nephropathy - damage to kidneys
macrovascular complications
coronary artery disease
stroke
peripheral arterial disease
neuropathic complications
lose neurons that signal an issue in the feet
type 1 diabetes
results of pancreatic beta cell destruction
prone to ketoacidosis
type 2 diabetes
insulin resistance with insulin deficiency
resulting in more glucose in the bloodstream because cant be taken up by cells
gestational diabetes
glucose intolerance with onset or first recognition during pregnancy higher risk of developing type 2 later in life
risk factors for type 2
over 40 first degree relative with type2 aboriginal, asain, african history of prediabetes or GDM delivery of macrosomic infant presence of end organ damage hypertension overweight polycystic ovary syndrome psychiatric disorder HIV OSA glucocorticoids atypical antopsychotics HAART
what is fasting plasma glucose
blood test performed when teh patient hasnt eater or drank for 8-10 hours
what is glycosylated hemoglobin
percentage of hemoglobin that is coated with sugar
reflects the avg blood glucose control for proceding 2-3 months
what is the oral glucose tolerance test
dose of glucose given to drink then blood glucose measured 2 hours after and before
determines bodys ability to break down and use carbs
diagnosis of diabetes
FPG =/>7
A1C =/> 6.5%
2hPG or random =/> 11.1
any one of the above
diagnosis of prediabetes
FPG 6.1-6.9
A1C 6-6.5%
OGTT 7.8 - 11
what is polycystic ovary syndrome
inappropriate gonadotropin secretion adn hyperinsulinemia results in excess androgen production and potential an anovulation
long term may lead to glucose intolerance, dyslipidemia, increased BP
who should be screened for type 2 diabetes
any over 40 every 3 years
if at high risk screen more often
who should be referred to an effective ongoign support program targeting 7% loss of body weight and increasing physical activity
patients with impaired glucose tolerance, impaired fasting glucose, and A1c of 5.7-6.4%
who should be considered for metformin therapy
IGT, IFG and A1c 5.7-6.4% wiht BMI >35, under 60 years olds and women who have had GDM
goals of treatment for diabetes
decrease/prevent symptoms
improve quality of life
reduce risk of micro/macrovascular complications
reduce mortality
metformin MOA
biguanide, acts as insulin sensiizer